Skip to main content

Intelligent Live Cell Analysis [iLCA] to transform disease management through faster, and more regulatory robust, discovery, manufacture and monitoring of biologic drugs & cell therapies

Objective

The detailed analysis of live cells, as shed elements of a human disease process, cell therapies themselves or as factories for the production of biologic drugs, is attracting intense focus globally from diverse companies in automation, imaging, diagnostics and manufacturing. This proposal is made on behalf of a consortium of 3 European SME’s to support the validation and preparation for commercial take-up of the market entry application, Cell Line Development [CLD], of a new transformative technology at the forefront of these areas and is ideally suited for cell line development, antibody discovery, gene editing, cell therapy, antibody engineering and ex-vivo diagnostic workflows. Each workflow provides a dramatic increase in insight, control, speed and cost, ultimately resulting in faster, cheaper and more regulatory robust medicines for European patients. Biologic drugs are large in size and are manufactured from a single cell selected following an expensive, relatively crude and time consuming process - Cell Line Development. Our technology can select the 'Top' cell using a detailed analysis of the critical quality attributes along with providing complete image recording and documentation of the growth from a single cell [regulatory requirement]. This cell selection and control is essential as all resulting master and working cell banks are used over the entire life‐cycle of the marketed product that can last multiple decades. This FTI funding will enable market entry and validation & support external fundraising for the wider penetration of the global drug discovery, Cell therapy & ex-vivo diagnostic markets. This is a potentially transformative technology platform in a very large market with 1 current aggressively funded US competitor and our success will ensure competition, continued innovation and most importantly cheaper medicines for European patients.

Field of science

  • /social sciences/sociology/industrial relations/automation
  • /medical and health sciences/medical biotechnology/cells technologies
  • /social sciences/economics and business/business and management/commerce

Call for proposal

H2020-EIC-FTI-2018-2020
See other projects for this call

Funding Scheme

IA - Innovation action

Coordinator

VALITACELL LTD
Address
Fosters Ave. - Mount Merrion, Blackrock
V94 Dublin 2
Ireland
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
EU contribution
€ 1 135 667,75

Participants (2)

SOLENTIM LTD
United Kingdom
EU contribution
€ 708 421,88
Address
Solent House 3 Johnson Road Fernsid
BH21 7SE Wimborne
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
MICROCOAT BIOTECHNOLOGIE GMBH
Germany
EU contribution
€ 594 454
Address
Am Neuland 3
82347 Bernried
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)